Allison Inserro

The update includes a broader, more integrated examination of other high and moderate penetrance genes associated with breast, ovarian, and pancreatic cancer.

The analysis estimates that in 2018, healthcare spending grew at a rate of 4.6% to $3.6 trillion, or $11,172 per person, faster than 2017’s 4.2% but equal to the 2016 rate.

A recent review examined the challenges of treating excessive daytime sleepiness due to obstructive sleep apnea (OSA) and narcolepsy.

Researchers used ultrasound to investigate the anatomical basis for arthralgia symptoms and found that tenosynovitis was the only significant difference in patients who went on to develop psoriatic arthritis (PsA).

The FDA Monday granted accelerated approval to voxelotor (Oxbryta) for the treatment of sickle cell disease in adults and pediatric patients 12 years or older.

Without information about the possible severity of their condition, patients with psoriasis may not adhere to treatment, which could lead to worse outcomes.

It has now become commonplace for families in America to struggle with their ability to keep children as healthy as possible due to factors related to social determinants of health, according to a new survey.

A recent study in the International Journal of Women’s Dermatology described the complex interplay of sex hormones in the pathways of metabolic syndrome (MetS) in pre- and postmenopausal women and how clinicians should be aware of the multiple factors of MetS.

There are substantial reductions in income over a lifetime for patients with sickle cell disease owing to early mortality, according to a new study that seeks to provide a better understanding of the condition from both the patient point of view as well as a societal point of view.

A team of researchers led by Memorial Sloan-Kettering Cancer Center Thursday published work describing how they used machine learning, a form of artificial intelligence (AI), to predict tumor type from targeted DNA sequence data to predict tissue of origin, in a finding that may have implications to improve diagnostic and clinical care.

Secondary analyses of data from the landmark CREDENCE trial show that the protective renal benefits of the SGLT2 inhibitor canagliflozin are greatest among type 2 diabetes patients with lower kidney function.

A poster presented at the American Society of Nephrology's (ASN) Kidney Week 2019 sought to understand more about patient knowledge of anemia and its impact on patient quality of life, their understanding of the disease, as well as how their anemia is managed.

As Kidney Week closed, nephrologists gathered to hear policy updates and information about forthcoming payment models from CMS and seemed pleased with what they heard.

The federal government wants to lower the rate of end-stage renal disease (ESRD) and improve kidney care outcomes, but such efforts will require earlier identification of chronic kidney disease (CKD), especially in veterans. At the American Society of Nephrology's (ASN) Kidney Week 2019, one poster described the gaps in identifying CKD in this population.

What should providers do about intentional nonadherence, and what strategies should they try to get their patients to take their hypertension medicine? At a session at the American Society of Nephrology (ASN)’s Kidney Week 2019, physicians discussed direct observation therapy (DOT), drug monitoring, case studies, and other published work about patients who don’t take their medications. Then they heard from a directly from a patient who shared why she stopped taking her medication and the scary consequence that developed as a result.

The age of psoriasis onset determines whether arthritis or psoriasis starts first in patients with psoriatic arthritis (PsA).

Patients receiving dialysis living in communities with a high percentage of black residents are known to have worse morbidity and mortality outcomes, and a study presented Saturday at the American Society of Nephrology Kidney Week 2019 meeting found that patients receiving dialysis in those communities also had higher hospitalization rates.

Perhaps not surprisingly, younger children had higher levels of parental support overall; the study also found that mothers provided more support than fathers.

The risk of major adverse cardiovascular events was comparable with placebo in patients not treated with dialysis who received the investigational drug roxadustat, according to pooled cardiovascular safety data about the first-in-class oral therapy for patients with chronic kidney disease (CKD).

A simple risk-assessment tool that helps physicians with early identification of patients at increased risk of chronic kidney disease (CKD) could lead to improved and targeted surveillance strategies, according to research published Friday.

Investigators presented data about 3 phase 3 trials of roxadustat at a national nephrology meeting to a standing-room only crowd, but the information the audience is really waiting to hear will have to wait until early Friday afternoon. While the trials showed promising results, day 2 of American Society of Nephrology's (ASN) Kidney Week 2019 will see the release of highly anticipated efficacy and pooled cardiovascular safety data about the first-in-class oral drug to treat chronic kidney disease in patients with anemia.

States can reduce Medicaid spending if the beneficiaries are also veterans, explains a veteran who started outreach in Washington state, which has since saved over $100 million since 2002.

HHS is taking additional steps to improve care for those with end-stage renal disease (ESRD), Secretary Alex Azar announced Thursday. Speaking at a tightly packed session during the American Society of Nephrology’s Kidney Week 2019, Azar said HHS is looking to speed organ transplants to those who need them as part of an overall shift away from dialysis in kidney care centers and as part of its overall desire to lower spending while improving outcomes.

Monoclonal gammopathy of undetermined significance, a precancerous blood condition that rarely progresses to myeloma, can be predicted by a pattern of frequent hospital visits, and finding it earlier could present an opportunity to begin myeloma treatment earlier, thus improving outcomes.

Microsoft is partnering with an independent, nonprofit biomedical research institution on an artificial intelligence, machine learning tool to process the vast amount of data flowing out of genomic research.

The Trump administration is supporting Stephen Hahn, MD, FASTRO, the chief medical officer of MD Anderson Cancer Center, as the next FDA commissioner, and the current acting commissioner, Ned Sharpless, MD, is returning to his old job as head of the National Cancer Institute (NCI).

A new review published in The Lancet describes the future landscape of therapeutics in development for what the authors call the next generation of HIV prevention, or PrEP 2.0.

A report released this week by the Kaiser Family Foundation illustrates how immigration policy changes at the federal level are affecting an increasing number of families, some of whom are disenrolling themselves and their children from California’s Medicaid program and not renewing or not enrolling in other programs, even though they are eligible and not directly affected by the policy changes. Experts are worried about long-term health effects.

The FDA released a report that finds 3 factors responsible for the problem, including a lack of incentives for manufacturers to produce less profitable drugs.

Quadruple therapy for newly diagnosed patients with multiple myeloma (MM) led to significantly longer progression-free survival (PFS), according to an abstract presented at the 17th International Myeloma Workshop 2019 in Boston, Massachusetts, last month.